Axxam at the Alzheimer’s & Parkinson’s Disease Conference 2025 – Advancing Neurodegenerative Research

Axxam is proud to attend the Alzheimer’s & Parkinson’s Disease Conference 2025, a key event driving innovation in neurodegenerative disease research and drug discovery. This conference brings together leading scientists, biotech pioneers, and pharmaceutical experts to discuss the latest breakthroughs in Alzheimer’s, Parkinson’s, and related disorders.

Our team, including Kerstin Schmitz, Business Development Manager and a  Stella Donato, Scientist, will engage with leading researchers and industry professionals to explore new strategies in target-based drug discovery, phenotypic screening, and biomarker-driven approaches.

We are especially excited to share our research through an accepted talk titled:

🧪 “Organelles in Focus: Therapeutic Approaches for Neurodegenerative Disorders.”

This presentation will explore novel strategies for targeting cellular organelles to develop disease-modifying therapies, reflecting Axxam’s commitment to pioneering new approaches in neuroscience drug discovery.

With expertise in high-throughput screening (HTS), iPSC-based models, and functional assays, Axxam supports the discovery of innovative therapeutics for neurodegenerative diseases. By leveraging high-content imaging, AI-driven analytics, and advanced screening technologies, we provide mechanistic insights into disease progression and therapeutic interventions. Our work spans small molecules, biologics, and pathway-targeting strategies, accelerating the path to new treatments.

This conference offers a great opportunity to connect with experts in neurodegeneration, discuss industry trends, and foster collaborations. If you’re attending, join us for the talk and let’s explore how Axxam’s expertise in neuroscience and early drug discovery can support your research goals. Stay tuned for updates and key takeaways from the event!